Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
0.9464
+0.0047 (0.50%)
At close: Oct 2, 2026, 4:00 PM EDT
0.9400
-0.0064 (-0.68%)
After-hours: Oct 2, 2026, 6:41 PM EDT
CELZ Revenue
Creative Medical Technology Holdings had revenue of $3.00K in the twelve months ending June 30, 2026, down -50.00% year-over-year. In the year 2025, Creative Medical Technology Holdings had annual revenue of $6.00K, down -45.45%.
Revenue (ttm)
$3.00K
Revenue Growth
-50.00%
P/S Ratio
2,079.73
Revenue / Employee
$750
Employees
4
Market Cap
6.24M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.00K | -5.00K | -45.45% |
| Dec 31, 2024 | 11.00K | 2.00K | 22.22% |
| Dec 31, 2023 | 9.00K | -79.60K | -89.84% |
| Dec 31, 2022 | 88.60K | 846.00 | 0.96% |
| Dec 31, 2021 | 87.75K | -76.75K | -46.65% |
| Dec 31, 2020 | 164.50K | -1.00K | -0.60% |
| Dec 31, 2019 | 165.50K | 41.10K | 33.04% |
| Dec 31, 2018 | 124.40K | 119.60K | 2,491.67% |
| Dec 31, 2017 | 4.80K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 4.70M |
| Evogene | 1.66M |
| Can-Fite BioPharma | 405.00K |
| CollPlant Biotechnologies | 318.00K |
| AIM ImmunoTech | 95.00K |
| Cardio Diagnostics Holdings | 14.45K |
| Pulmatrix | 3.00K |
CELZ News
- 16 days ago - Creative Medical files new U.S. provisional patent application for Ultrasome - TheFly
- 16 days ago - Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing - GlobeNewsWire
- 6 weeks ago - Roth believes Creative Medical’s ADAPT trial in CLBO ‘likely to succeed’ - TheFly
- 6 weeks ago - Creative Medical completes enrollment in ADAPT clinical trial - TheFly
- 6 weeks ago - Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning - GlobeNewsWire
- 1 month ago - Creative Medical receives notice of allowance for new U.S. patent - TheFly
- 1 month ago - Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms - GlobeNewsWire
- 2 months ago - Creative Medical files to sell 5.58M shares of common stock for holders - TheFly